This latest pipeline guide provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
- Appili Therapeutics Inc
- Aradigm Corp
- DynPort Vaccine Company LLC
- Emergent BioSolutions Inc
- EpiVax Inc
- Grifols SA
- Tetraphase Pharmaceuticals Inc
Key Topics Covered
- Report Coverage
- Tularaemia - Overview
- Tularaemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tularaemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tularaemia - Companies Involved in Therapeutics Development
- Tularaemia - Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/research/j9kmf5/2018_tularaemia?w=4